Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06079424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Risk Markers of Arterial Aging. The Paris Prospective Study III-2

Study acronym: PPS3-2
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: details revised at 3 of 10 entries
    • Site details revised
    • Eligibility criteria expanded, about 4 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2025 to Jun 20, 2025
    v3
  3. Primary completion date: Jun 2027 to May 2031
    • Start date: Jun 2024 to May 2025
    • Study completion date: Dec 2037 to Dec 2033
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objectives of PPS3-2 are (i) to describe the dynamics of vascular aging and baroreflex sensitivity 12 to 16 years a part, (ii) to identify their determinants, and (iii) to quantify the subsequent risk of cardiovascular diseases.
Trial Details
NCT Number NCT06079424
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Conditions
(from sponsor)		 Arterial Stiffness
Related terms Cardiovascular Diseases
Enrollment 7,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov